{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T10:50:46Z","timestamp":1782211846953,"version":"3.54.5"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Oligometastatic prostate cancer (OMPC) is typically treated with systemic therapy, which may be complemented by radiotherapy (RT) of the prostate as part of primary directed therapy (PDT). This study retrospectively evaluated clinical outcomes following PDT in OMPC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twenty-four consecutive patients who underwent PDT for OMPC between 2011 and 2023 were analyzed retrospectively. The primary endpoint was progression-free survival (PFS); secondary endpoints included biochemical PFS (bPFS), overall survival (OS), and treatment-related toxicity. Survival was estimated using Kaplan\u2013Meier analysis, and prognostic factors for PFS were assessed using univariate log-rank tests and multivariate Cox regression. The median follow-up was 40 months. Median age was 75 years (range: 58\u201383), with a median of two metastases (range: 1\u20135). Nineteen patients (79%) were staged with PSMA-PET\/CT; 20 had synchronous and 20 low-burden disease (CHAARTED criteria). The most common RT regimen was 60\u00a0Gy in 20 fractions. Twenty-three patients received androgen deprivation therapy (ADT), including six with an androgen receptor signaling inhibitor (median duration: 23 months). Additionally, 22 underwent metastasis-directed therapy (MDT), and five elective nodal RT. Median PFS and bPFS were 80 and 73 months, respectively; median OS was not reached. Three-year PFS, bPFS, and OS were 78%, 81%, and 84%. Low metastatic burden (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.007) and synchronous metastases (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.027) predicted longer PFS. No acute grade 3 toxicity occurred; late grade 3 gastrointestinal and genitourinary toxicity occurred in 8% each.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this predominantly PSMA-PET\/CT-staged cohort, PDT combined with MDT and ADT achieved promising long-term outcomes with acceptable toxicity, warranting confirmation in larger prospective studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13550-026-01473-1","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T10:14:20Z","timestamp":1782209660000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcome after primary directed radiotherapy in predominantly PSMA-PET\/CT-staged patients with metastatic prostate cancer"],"prefix":"10.1186","volume":"16","author":[{"given":"Christian","family":"Trapp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Frederike","family":"Brose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Keilholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minglun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina-Sophie","family":"Schmidt-Hegemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Belka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Weinhold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jozefina","family":"Casuscelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Stief","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3351-8896","authenticated-orcid":false,"given":"Paul","family":"Rogowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"1473_CR1","unstructured":"Koch-Institut R. Krebs in Deutschland f\u00fcr 2019\/2020 [de]; 2023."},{"key":"1473_CR2","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Krebshilfe D, AWMF). : S3-Leitlinie Prostatakarzinom, Langversion 8.1, 2025, AWMF-Registernummer: 043-022OL https:\/\/www.leitlinienprogrammonkologie.de\/leitlinien\/prostatakarzinom\/; Zugriff am [tt.mm.jjj]. Available from: https:\/\/www.leitlinienprogrammonkologie.de\/leitlinien\/prostatakarzinom\/; Zugriff am [tt.mm.jjj]."},{"key":"1473_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.09.008","author":"LM Boev\u00e9","year":"2019","unstructured":"Boev\u00e9 LM, Hulshof M, Vis AN, Zwinderman AH, Twisk JW, Witjes WP, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. Eur Urol. 2019. https:\/\/doi.org\/10.1016\/j.eururo.2018.09.008.","journal-title":"Eur Urol"},{"key":"1473_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32486-3","author":"CC Parker","year":"2018","unstructured":"Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial [eng]. Lancet. 2018. https:\/\/doi.org\/10.1016\/S0140-6736(18)32486-3.","journal-title":"Lancet"},{"key":"1473_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01865-8","author":"A Bossi","year":"2024","unstructured":"Bossi A, Foulon S, Maldonado X, Sargos P, MacDermott R, Kelly P, et al. Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design [eng]. Lancet. 2024. https:\/\/doi.org\/10.1016\/S0140-6736(24)01865-8.","journal-title":"Lancet"},{"key":"1473_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30314-7","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study [eng]. Lancet. 2020. https:\/\/doi.org\/10.1016\/S0140-6736(20)30314-7.","journal-title":"Lancet"},{"key":"1473_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30718-1","author":"M Guckenberger","year":"2020","unstructured":"Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation [eng]. Lancet Oncol. 2020. https:\/\/doi.org\/10.1016\/S1470-2045(19)30718-1.","journal-title":"Lancet Oncol"},{"key":"1473_CR8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281053","author":"World Medical Association Declaration of Helsinki","year":"2013","unstructured":"World Medical Association Declaration of Helsinki. JAMA. 2013. https:\/\/doi.org\/10.1001\/jama.2013.281053. : ethical principles for medical research involving human subjects [eng]."},{"key":"1473_CR9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503747","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen Y-H, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer [eng]. N Engl J Med. 2015. https:\/\/doi.org\/10.1056\/NEJMoa1503747.","journal-title":"N Engl J Med"},{"key":"1473_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.02.003","author":"S Burdett","year":"2019","unstructured":"Burdett S, Boev\u00e9 LM, Ingleby FC, Fisher DJ, Rydzewska LH, Vale CL, et al. Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis [eng]. Eur Urol. 2019. https:\/\/doi.org\/10.1016\/j.eururo.2019.02.003.","journal-title":"Eur Urol"},{"key":"1473_CR11","unstructured":"EAU Guidelines. Edn. presented at the EAU Annual Congress Madrid 2025. ISBN 978-94-92671-29-5."},{"key":"1473_CR12","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2017.786","author":"G Riva","year":"2017","unstructured":"Riva G, Marvaso G, Augugliaro M, Zerini D, Fodor C, Musi G, et al. Cytoreductive prostate radiotherapy in oligometastatic prostate cancer: a single centre analysis of toxicity and clinical outcome [eng]. Ecancermedicalscience. 2017. https:\/\/doi.org\/10.3332\/ecancer.2017.786.","journal-title":"Ecancermedicalscience"},{"key":"1473_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-021-00339-y","author":"SC Morgan","year":"2021","unstructured":"Morgan SC, Holmes OE, Craig J, Grimes S, Malone S. Long-term outcomes of prostate radiotherapy for newly-diagnosed metastatic prostate cancer [eng]. Prostate Cancer Prostatic Dis. 2021. https:\/\/doi.org\/10.1038\/s41391-021-00339-y.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1473_CR14","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20190353","author":"CL Deantoni","year":"2020","unstructured":"Deantoni CL, Fodor A, Cozzarini C, Fiorino C, Brombin C, Di Serio C, et al. Prostate cancer with low burden skeletal disease at diagnosis: outcome of concomitant radiotherapy on primary tumor and metastases [eng]. Br J Radiol. 2020. https:\/\/doi.org\/10.1259\/bjr.20190353.","journal-title":"Br J Radiol"},{"key":"1473_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-74562-3","author":"C Reverberi","year":"2020","unstructured":"Reverberi C, Massaro M, Osti MF, Anzellini D, Marinelli L, Montalto A, et al. Local and metastatic curative radiotherapy in patients with de novo oligometastatic prostate cancer [eng]. Sci Rep. 2020. https:\/\/doi.org\/10.1038\/s41598-020-74562-3.","journal-title":"Sci Rep"},{"key":"1473_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2020.06.018","author":"BS Imber","year":"2020","unstructured":"Imber BS, Varghese M, Goldman DA, Zhang Z, Gewanter R, Marciscano AE, et al. Clinical Outcomes of Combined Prostate- and Metastasis-Directed Radiation Therapy for the Treatment of De Novo Oligometastatic Prostate Cancer [eng]. Adv Radiat Oncol. 2020. https:\/\/doi.org\/10.1016\/j.adro.2020.06.018.","journal-title":"Adv Radiat Oncol"},{"key":"1473_CR17","doi-asserted-by":"publisher","DOI":"10.5603\/RPOR.a2021.0077","author":"A Montero","year":"2021","unstructured":"Montero A, Hernando O, Ca\u00f1on V, Guevara D, Valero J, Chen-Zhao X, et al. Radiation therapy with curative intention in men with de novo metastatic prostate carcinoma: shoot\u2019em all! [eng]. Rep Pract Oncol Radiother. 2021. https:\/\/doi.org\/10.5603\/RPOR.a2021.0077.","journal-title":"Rep Pract Oncol Radiother"},{"key":"1473_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/jrr\/rraa056","author":"K Inaba","year":"2021","unstructured":"Inaba K, Tsuchida K, Kashihara T, Umezawa R, Takahashi K, Okuma K, et al. Treatment results of radiotherapy to both the prostate and metastatic sites in patients with bone metastatic prostate cancer [eng]. J Radiat Res. 2021. https:\/\/doi.org\/10.1093\/jrr\/rraa056.","journal-title":"J Radiat Res"},{"key":"1473_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1607610","author":"DM Poon","year":"2025","unstructured":"Poon DM, Yuan J, Wong OL, Yang B, Chiu ST, Cheung KY, et al. Stereotactic total ablative radiotherapy with MR-LINAC for synchronous oligometastatic prostate cancer [eng]. Front Oncol. 2025. https:\/\/doi.org\/10.3389\/fonc.2025.1607610.","journal-title":"Front Oncol"},{"key":"1473_CR20","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0147","author":"R Phillips","year":"2020","unstructured":"Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES, et al. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial [eng]. JAMA Oncol. 2020. https:\/\/doi.org\/10.1001\/jamaoncol.2020.0147.","journal-title":"JAMA Oncol"},{"key":"1473_CR21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.4853","author":"P Ost","year":"2018","unstructured":"Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, de Bruycker A, et al. Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial [eng]. JCO. 2018. https:\/\/doi.org\/10.1200\/JCO.2017.75.4853.","journal-title":"JCO"},{"key":"1473_CR22","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.0161","author":"C Tang","year":"2023","unstructured":"Tang C, Sherry AD, Haymaker C, Bathala T, Liu S, Fellman B, et al. Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial [eng]. JAMA Oncol. 2023. https:\/\/doi.org\/10.1001\/jamaoncol.2023.0161.","journal-title":"JAMA Oncol"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-026-01473-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-026-01473-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-026-01473-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T10:35:33Z","timestamp":1782210933000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13550-026-01473-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1473"],"URL":"https:\/\/doi.org\/10.1186\/s13550-026-01473-1","relation":{"references":[{"id-type":"doi","id":"10.1001\/jama.2013.281053","asserted-by":"subject"}]},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"5 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective analysis was approved by the local ethics committee (LMU 25\u20130429). Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Generative AI and AI-assisted technologies were used in the preparation of this manuscript to support language refinement, text structuring, and translation. The authors take full responsibility for the content, have critically reviewed all text, and approved the final version of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement on the use of generative AI and AI-assisted technologies in the writing process"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare that they have no conflicts of interest or competing interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"100"}}